Treatment with the CCR5 antagonist OB-002 reduces lung pathology, but does not prevent disease in a Syrian hamster model of SARS-CoV-2 infection.

Treatment with the CCR5 antagonist OB-002 reduces lung pathology, but does not prevent disease in a Syrian hamster model of SARS-CoV-2 infection.

Since the emergence of SARS-CoV-2 and the COVID-19 pandemic, a wide range of treatment options have been evaluated in preclinical studies and clinical trials, with several being approved for use in humans. Immunomodulatory drugs have shown success in dampening the deleterious inflammatory response s...

Full description

Saved in:
Bibliographic Details
Main Authors: Bryce M Warner, Robert Vendramelli, Amrit S Boese, Jonathan Audet, Nikesh Tailor, Courtney Meilleur, Nathan Glowach, Marnie Willman, Thang Truong, Estella Moffat, Kevin Tierney, Beata Kosak, Irfan Dhanidina, Jarret Engstrom, Bozena Korczak, Ian McGowan, Carissa Embury-Hyatt, Darwyn Kobasa
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0316952
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1371/journal.pone.0316952

Similar Items